Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer
NCT04149444Phase 2Withdrawn
- Sponsor
- American Health Staffing Group
- Start
- Feb 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil in triple-negative breast cancer (TNBC), sponsored by American Health Staffing Group. Planned start Feb 2020; status: withdrawn.
02
Drugs
trifluridine + tipiracil
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04149444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04149444.